In this article
CJC/Ipamorelin is a two-component blend, while GHRP-6 is a different single compound. Comparing them in Bali requires more than choosing between two “GH peptides.” The ingredients address related signalling questions, but evidence about a receptor or hormone response does not automatically establish better recovery, less hunger or a safer finished product.
Compare like with like
The catalogue's CJC/Ipamorelin pen contains 10 mg of each component, 20 mg total. GHRP-6 is not another name for either that blend or its CJC component. A comparison that labels both simply “20 mg peptides” would hide the most important difference.
| Feature | CJC/Ipamorelin listing | GHRP-6 |
|---|---|---|
| Number of components | Two | One |
| Main identity question | Which CJC form, plus ipamorelin? | Exact GHRP-6 preparation |
| Meaning of total milligrams | Sum of two labelled ingredients | Amount of one compound |
| Evidence required for an outcome | Evidence relevant to the actual blend | Evidence relevant to the actual compound |
GHRP-6 is discussed as a comparator here; it is not sold in this catalogue.
What “selective” meant in ipamorelin research
The original ipamorelin selectivity paper compared experimental hormone responses with other growth-hormone-releasing peptides, including GHRP-6. It studied particular laboratory and experimental conditions. A more selective response in those settings is not a guarantee that a retail pen has no unwanted effects.
That is especially important when a comparison reduces the decision to “hunger versus no hunger” or “cortisol versus no cortisol.” Those claims need relevant human evidence, a specified preparation and a defined outcome. A receptor description cannot supply all three.
The CJC component adds another identification problem
The human CJC-1295 publication studied a long-acting compound and measured GH and IGF-1 responses. Online product names do not always make the distinction between CJC-related forms clear. Evidence for the long-acting research preparation should not be silently applied to every no-DAC label or blended pen.
Ask which form the product contains and which source supports the claim being made. The CJC-1295 DAC versus no-DAC article explains why that detail changes how a citation should be read.
A hormone result is not a recovery result
If your goal is returning to training, the meaningful question may be pain, function or performance. If your concern is sleep, it may be a sleep measurement. Neither is automatically answered by a rise in GH or IGF-1.
Ipamorelin has also been studied for postoperative bowel function. That is human research, but it concerns a different clinical situation from a healthy visitor choosing a performance product. The presence of a human study matters less than whether it answers the question you are actually asking.
How to compare an offer in Bali
Start with the CJC/Ipamorelin product page and record the exact ingredient names. Separate questions about what is supplied from questions about whether it is appropriate for you. A seller can identify the product; clinical assessment is needed for an individual treatment decision.
Bring the intended outcome and any previous experience to that assessment. If an offer claims improved recovery, ask what “recovery” means in its evidence. A laboratory marker, an athlete's testimonial and a controlled functional outcome are not interchangeable support.
For a short stay, explain how follow-up will work after you leave. Do not use the fact that two products appear in the same online category as a reason to alternate or combine them. Shared marketing labels do not establish a compatible regimen.
A useful evidence request also asks how unwanted effects were collected and how long participants were followed. A short hormone-response experiment and a longer clinical assessment answer different safety questions. Absence of a reported event in one small study is not proof that an event cannot occur with another preparation.
FAQ
Is GHRP-6 a cheaper spelling of ipamorelin?
No. They are different compounds. The comparison must use their actual identities rather than treating the names as brand variants.
Does selectivity mean that side effects are impossible?
No. Selectivity describes a measured pattern under specified conditions, not a universal safety promise.
Is 10 mg plus 10 mg the same as 20 mg of one peptide?
No. The total is arithmetic; the ingredients remain different. It is not a conversion between products or a dosing equivalence.
Can a CJC-only study prove the combination works better?
It can inform the CJC component's research context, but cannot by itself establish a clinical advantage for the finished CJC/Ipamorelin blend.
Sources
- Ipamorelin, the first selective growth hormone secretagogue
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults
- Prospective, randomized, controlled, proof-of-concept study of ipamorelin for postoperative ileus
Source and editorial checks completed. How these articles are prepared.
